Did you mean category antidepressive agen and group approved?
Displaying drugs 601 - 625 of 9424 in total
Guanfacine
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
Approved
Investigational
Matched Description: … receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an …
Etacrynic acid
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop...
Approved
Investigational
Histrelin
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that...
Approved
Withdrawn
Matched Description: … gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an ... As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by ... [L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this …
Burosumab
Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets .
The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018. This is the first drug approved...
Approved
Investigational
Matched Description: … Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor ... Food and Drug Administration approved Crysvita (burosumab) in April 2018. ... This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia …
Safinamide
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Approved
Investigational
Matched Description: … It was approved in Europe in February 2015, and in the United States on March 21, 2017. …
Matched Categories: … Antidepressive Agents …
Matched Categories: … Antidepressive Agents …
Eflornithine
Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells.[A4112, A262834] Additionally, ornithine decarboxylase is activated by c-myc or...
Approved
Withdrawn
Matched Description: … Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment ... [A262839]
In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA ... [A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the …
Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (formaldehyde inactivated)
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an …
Omega-3-carboxylic acids
The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. The increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl...
Approved
Investigational
Matched Description: … The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced ... [A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014 …
Susoctocog alfa
Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the...
Approved
Investigational
Matched Description: … B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved ... It is the first recombinant porcine FVIII treatment approved for AHA that allows physicians to manage ... Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for …
Tapentadol
Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596]
Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011....
Approved
Matched Description: … [A260721, A36596]
Tapentadol was first approved by the FDA on November 20, 2008. ... The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. …
Matched Categories: … Antidepressive Agents …
Matched Categories: … Antidepressive Agents …
Lesinurad
Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with...
Approved
Investigational
Matched Description: … In August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under ... Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia ... It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake …
Avalglucosidase alfa
Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase (GAA) enzyme. GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. In Pompe disease, the...
Approved
Investigational
Matched Description: … GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. ... [L39205] The EMA approved the drug on June 24, 2022.[L42720] ... [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of …
Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an …
Nitrofurantoin
Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections.[L6856,L6859,L6862] Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts...
Approved
Vet approved
Flurbiprofen
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis....
Approved
Investigational
Matched Description: … Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic …
Bepotastine
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available...
Approved
Matched Description: … The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. ... Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus …
Ripretinib
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Description: … [L13769]
It is the first drug approved as a fourth-line therapy in the specific setting of prior ... Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved …
Hydralazine
Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a...
Approved
Matched Description: … [T691]
Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779] …
Indigotindisulfonic acid
Indigotindisulfonic acid is a blue-colored dye with a variety of uses.[A32490,A32491,A32492,L2222] Its salt form, indigotindisulfonate sodium, is also known as indigo carmine, indigotine or FD&C Blue #2. This compound is an acid-base indicator and is used in the production of food colorants and pH tests. Indigotindisulfonic acid is used in...
Approved
Investigational
Matched Description: … This compound is an acid-base indicator and is used in the production of food colorants and pH tests. ... [A32490,A32491,A32492] In 2022, the FDA approved the intravenous use of indigotindisulfonate sodium to …
Abemaciclib
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Description: … Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6 …
Nonacog beta pegol
Nonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). Nonacog...
Approved
Investigational
Matched Description: … [L41185] Nonacog beta pegol was approved by Health Canada on November 29, 2017.[L43682] ... It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) …
Penicillamine
Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.
Approved
Matched Description: … It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties. …
Azelastine
Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic conjunctivitis.[L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first...
Approved
Matched Description: … Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment ... of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic conjunctivitis …
Oritavancin
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of...
Approved
Investigational
Matched Description: … [A39384,A193482,L8492]
On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in ... [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion ... [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive …
Displaying drugs 601 - 625 of 9424 in total